2VWN - JenaLib

Asymmetric Unit (4, 6)

No.	Name	Count	Type	Full Name
1	CA	1	Ligand/Ion	CALCIUM ION
2	CL	2	Ligand/Ion	CHLORIDE ION
3	H25	1	Ligand/Ion	5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-4-HYDROXY-PYRROLIDIN-3-YL)-AMIDE
4	NA	2	Ligand/Ion	SODIUM ION

Biological Unit 1 (1, 1)

No.	Name	Count	Type	Full Name
1	CA	-1	Ligand/Ion	CALCIUM ION
2	CL	-1	Ligand/Ion	CHLORIDE ION
3	H25	1	Ligand/Ion	5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-4-HYDROXY-PYRROLIDIN-3-YL)-AMIDE
4	NA	-1	Ligand/Ion	SODIUM ION

Biological Unit 2 (1, 1)

No.	Name	Count	Type	Full Name
1	CA	-1	Ligand/Ion	CALCIUM ION
2	CL	-1	Ligand/Ion	CHLORIDE ION
3	H25	1	Ligand/Ion	5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-4-HYDROXY-PYRROLIDIN-3-YL)-AMIDE
4	NA	-1	Ligand/Ion	SODIUM ION

Biological Unit 3 (0, 0)

No.	Name	Count	Type	Full Name
1	CA	-1	Ligand/Ion	CALCIUM ION
2	CL	-1	Ligand/Ion	CHLORIDE ION
3	H25	-1	Ligand/Ion	5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID ((3S,4S)-1-{[2-FLUORO-4-(2-OXO-2H-PYRIDIN-1-YL)-PHENYLCARBAMOYL]-METHYL}-4-HYDROXY-PYRROLIDIN-3-YL)-AMIDE
4	NA	-1	Ligand/Ion	SODIUM ION

Sites (6, 6)

SS Bonds (8, 8)

Cis Peptide Bonds (0, 0)

Sequence-Structure Mapping

SAPs(SNPs)/Variants (23, 23)

Asymmetric Unit (23, 23)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_075213	G	262	D	FA10_HUMAN	Unclassified (FA10D)	---	A	G	43	D
02	UniProt	VAR_065437	G	289	R	FA10_HUMAN	Disease (FA10D)	121964946	A	G	69	R
03	UniProt	VAR_065438	E	304	K	FA10_HUMAN	Disease (FA10D)	747292771	A	E	84	K
04	UniProt	VAR_065434	E	142	K	FA10_HUMAN	Unclassified (FA10D)	61753266	L	E	102	K
05	UniProt	VAR_065439	D	322	N	FA10_HUMAN	Disease (FA10D)	121964942	A	D	102	N
06	UniProt	VAR_065440	R	327	W	FA10_HUMAN	Disease (FA10D)	770119164	A	R	107	W
07	UniProt	VAR_065435	C	149	Y	FA10_HUMAN	Disease (FA10D)	---	L	C	109	Y
08	UniProt	VAR_065436	C	151	Y	FA10_HUMAN	Disease (FA10D)	---	L	C	111	Y
09	UniProt	VAR_020176	A	152	T	FA10_HUMAN	Polymorphism	3211772	L	A	112	T
10	UniProt	VAR_065441	V	338	M	FA10_HUMAN	Disease (FA10D)	121964947	A	V	118	M
11	UniProt	VAR_065442	E	350	K	FA10_HUMAN	Disease (FA10D)	372309538	A	E	129	K
12	UniProt	VAR_065443	T	358	M	FA10_HUMAN	Disease (FA10D)	768222784	A	T	135	M
13	UniProt	VAR_065444	G	363	S	FA10_HUMAN	Disease (FA10D)	---	A	G	140	S
14	UniProt	VAR_065445	R	366	C	FA10_HUMAN	Disease (FA10D)	104894392	A	R	143	C
15	UniProt	VAR_065446	S	374	P	FA10_HUMAN	Disease (FA10D)	121964941	A	S	152	P
16	UniProt	VAR_072751	V	382	A	FA10_HUMAN	Disease (FA10D)	---	A	V	160	A
17	UniProt	VAR_065447	P	383	S	FA10_HUMAN	Disease (FA10D)	121964940	A	P	161	S
18	UniProt	VAR_065448	C	390	F	FA10_HUMAN	Disease (FA10D)	199778916	A	C	168	F
19	UniProt	VAR_065449	C	404	R	FA10_HUMAN	Disease (FA10D)	---	A	C	182	R
20	UniProt	VAR_065450	G	406	S	FA10_HUMAN	Disease (FA10D)	376163818	A	G	184	S
21	UniProt	VAR_065451	G	420	R	FA10_HUMAN	Disease (FA10D)	750759634	A	G	196	R
22	UniProt	VAR_072752	G	421	D	FA10_HUMAN	Disease (FA10D)	758726161	A	G	197	D
23	UniProt	VAR_065452	K	448	N	FA10_HUMAN	Disease (FA10D)	---	A	K	224	N

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

Biological Unit 1 (23, 23)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_075213	G	262	D	FA10_HUMAN	Unclassified (FA10D)	---	A	G	43	D
02	UniProt	VAR_065437	G	289	R	FA10_HUMAN	Disease (FA10D)	121964946	A	G	69	R
03	UniProt	VAR_065438	E	304	K	FA10_HUMAN	Disease (FA10D)	747292771	A	E	84	K
04	UniProt	VAR_065434	E	142	K	FA10_HUMAN	Unclassified (FA10D)	61753266	L	E	102	K
05	UniProt	VAR_065439	D	322	N	FA10_HUMAN	Disease (FA10D)	121964942	A	D	102	N
06	UniProt	VAR_065440	R	327	W	FA10_HUMAN	Disease (FA10D)	770119164	A	R	107	W
07	UniProt	VAR_065435	C	149	Y	FA10_HUMAN	Disease (FA10D)	---	L	C	109	Y
08	UniProt	VAR_065436	C	151	Y	FA10_HUMAN	Disease (FA10D)	---	L	C	111	Y
09	UniProt	VAR_020176	A	152	T	FA10_HUMAN	Polymorphism	3211772	L	A	112	T
10	UniProt	VAR_065441	V	338	M	FA10_HUMAN	Disease (FA10D)	121964947	A	V	118	M
11	UniProt	VAR_065442	E	350	K	FA10_HUMAN	Disease (FA10D)	372309538	A	E	129	K
12	UniProt	VAR_065443	T	358	M	FA10_HUMAN	Disease (FA10D)	768222784	A	T	135	M
13	UniProt	VAR_065444	G	363	S	FA10_HUMAN	Disease (FA10D)	---	A	G	140	S
14	UniProt	VAR_065445	R	366	C	FA10_HUMAN	Disease (FA10D)	104894392	A	R	143	C
15	UniProt	VAR_065446	S	374	P	FA10_HUMAN	Disease (FA10D)	121964941	A	S	152	P
16	UniProt	VAR_072751	V	382	A	FA10_HUMAN	Disease (FA10D)	---	A	V	160	A
17	UniProt	VAR_065447	P	383	S	FA10_HUMAN	Disease (FA10D)	121964940	A	P	161	S
18	UniProt	VAR_065448	C	390	F	FA10_HUMAN	Disease (FA10D)	199778916	A	C	168	F
19	UniProt	VAR_065449	C	404	R	FA10_HUMAN	Disease (FA10D)	---	A	C	182	R
20	UniProt	VAR_065450	G	406	S	FA10_HUMAN	Disease (FA10D)	376163818	A	G	184	S
21	UniProt	VAR_065451	G	420	R	FA10_HUMAN	Disease (FA10D)	750759634	A	G	196	R
22	UniProt	VAR_072752	G	421	D	FA10_HUMAN	Disease (FA10D)	758726161	A	G	197	D
23	UniProt	VAR_065452	K	448	N	FA10_HUMAN	Disease (FA10D)	---	A	K	224	N

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

Biological Unit 2 (19, 19)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_075213	G	262	D	FA10_HUMAN	Unclassified (FA10D)	---	A	G	43	D
02	UniProt	VAR_065437	G	289	R	FA10_HUMAN	Disease (FA10D)	121964946	A	G	69	R
03	UniProt	VAR_065438	E	304	K	FA10_HUMAN	Disease (FA10D)	747292771	A	E	84	K
05	UniProt	VAR_065439	D	322	N	FA10_HUMAN	Disease (FA10D)	121964942	A	D	102	N
06	UniProt	VAR_065440	R	327	W	FA10_HUMAN	Disease (FA10D)	770119164	A	R	107	W
10	UniProt	VAR_065441	V	338	M	FA10_HUMAN	Disease (FA10D)	121964947	A	V	118	M
11	UniProt	VAR_065442	E	350	K	FA10_HUMAN	Disease (FA10D)	372309538	A	E	129	K
12	UniProt	VAR_065443	T	358	M	FA10_HUMAN	Disease (FA10D)	768222784	A	T	135	M
13	UniProt	VAR_065444	G	363	S	FA10_HUMAN	Disease (FA10D)	---	A	G	140	S
14	UniProt	VAR_065445	R	366	C	FA10_HUMAN	Disease (FA10D)	104894392	A	R	143	C
15	UniProt	VAR_065446	S	374	P	FA10_HUMAN	Disease (FA10D)	121964941	A	S	152	P
16	UniProt	VAR_072751	V	382	A	FA10_HUMAN	Disease (FA10D)	---	A	V	160	A
17	UniProt	VAR_065447	P	383	S	FA10_HUMAN	Disease (FA10D)	121964940	A	P	161	S
18	UniProt	VAR_065448	C	390	F	FA10_HUMAN	Disease (FA10D)	199778916	A	C	168	F
19	UniProt	VAR_065449	C	404	R	FA10_HUMAN	Disease (FA10D)	---	A	C	182	R
20	UniProt	VAR_065450	G	406	S	FA10_HUMAN	Disease (FA10D)	376163818	A	G	184	S
21	UniProt	VAR_065451	G	420	R	FA10_HUMAN	Disease (FA10D)	750759634	A	G	196	R
22	UniProt	VAR_072752	G	421	D	FA10_HUMAN	Disease (FA10D)	758726161	A	G	197	D
23	UniProt	VAR_065452	K	448	N	FA10_HUMAN	Disease (FA10D)	---	A	K	224	N

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

Biological Unit 3 (4, 4)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
04	UniProt	VAR_065434	E	142	K	FA10_HUMAN	Unclassified (FA10D)	61753266	L	E	102	K
07	UniProt	VAR_065435	C	149	Y	FA10_HUMAN	Disease (FA10D)	---	L	C	109	Y
08	UniProt	VAR_065436	C	151	Y	FA10_HUMAN	Disease (FA10D)	---	L	C	111	Y
09	UniProt	VAR_020176	A	152	T	FA10_HUMAN	Polymorphism	3211772	L	A	112	T

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

PROSITE Motifs (4, 4)

Asymmetric Unit (4, 4)

	PROSITE			UniProtKB		PDB
No.	ID	AC	Description	ID	Location	Count	Location
1	EGF_2	PS01186	EGF-like domain signature 2.	FA10_HUMAN	110-121 149-164	1	- L:109-124
2	TRYPSIN_DOM	PS50240	Serine proteases, trypsin domain profile.	FA10_HUMAN	235-467	1	A:16-243
3	TRYPSIN_HIS	PS00134	Serine proteases, trypsin family, histidine active site.	FA10_HUMAN	272-277	1	A:53-58
4	TRYPSIN_SER	PS00135	Serine proteases, trypsin family, serine active site.	FA10_HUMAN	413-424	1	A:189-200

Biological Unit 1 (4, 4)

	PROSITE			UniProtKB		PDB
No.	ID	AC	Description	ID	Location	Count	Location
1	EGF_2	PS01186	EGF-like domain signature 2.	FA10_HUMAN	110-121 149-164	1	- L:109-124
2	TRYPSIN_DOM	PS50240	Serine proteases, trypsin domain profile.	FA10_HUMAN	235-467	1	A:16-243
3	TRYPSIN_HIS	PS00134	Serine proteases, trypsin family, histidine active site.	FA10_HUMAN	272-277	1	A:53-58
4	TRYPSIN_SER	PS00135	Serine proteases, trypsin family, serine active site.	FA10_HUMAN	413-424	1	A:189-200

Biological Unit 2 (3, 3)

	PROSITE			UniProtKB		PDB
No.	ID	AC	Description	ID	Location	Count	Location
1	EGF_2	PS01186	EGF-like domain signature 2.	FA10_HUMAN	110-121 149-164	0	- -
2	TRYPSIN_DOM	PS50240	Serine proteases, trypsin domain profile.	FA10_HUMAN	235-467	1	A:16-243
3	TRYPSIN_HIS	PS00134	Serine proteases, trypsin family, histidine active site.	FA10_HUMAN	272-277	1	A:53-58
4	TRYPSIN_SER	PS00135	Serine proteases, trypsin family, serine active site.	FA10_HUMAN	413-424	1	A:189-200

Biological Unit 3 (1, 1)

	PROSITE			UniProtKB		PDB
No.	ID	AC	Description	ID	Location	Count	Location
1	EGF_2	PS01186	EGF-like domain signature 2.	FA10_HUMAN	110-121 149-164	1	- L:109-124
2	TRYPSIN_DOM	PS50240	Serine proteases, trypsin domain profile.	FA10_HUMAN	235-467	0	-
3	TRYPSIN_HIS	PS00134	Serine proteases, trypsin family, histidine active site.	FA10_HUMAN	272-277	0	-
4	TRYPSIN_SER	PS00135	Serine proteases, trypsin family, serine active site.	FA10_HUMAN	413-424	0	-

Exons (4, 5)

Sequences/Alignments

Asymmetric Unit

Reformat:	Number of residues per line = ('0' or empty: single-line sequence representation)
	Number of residues per labelling interval =
	UniProt sequence: complete aligned part

Show mapping:	SCOP domains	CATH domains	Pfam domains	Secondary structure (by author)
	SAPs(SNPs)	PROSITE motifs	Exons
	(details for a mapped element are shown in a popup box when the mouse pointer rests over it)

Chain A from PDB  Type:PROTEIN  Length:235
 aligned with FA10_HUMAN | P00742 from UniProtKB/Swiss-Prot  Length:488

    Alignment length:235
                                   244       254       264       274       284       294       304       314       324       334       344       354       364       374       384       394       404       414       424       434       444       454       464     
          FA10_HUMAN    235 IVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTR  469
               SCOP domains d2vwna_ A: automated matches                                                                                                                                                                                                                SCOP domains
               CATH domains 2vwnA01     2vwnA02 A:28-120,A:233-245 Trypsin-like serine proteases                                      2vwnA01 A:16-27,A:121-232 Trypsin-like serine proteases                                                             2vwnA02       CATH domains
               Pfam domains Trypsin-2vwnA01 A:16-238                                                                                                                                                                                                            ------- Pfam domains
         Sec.struct. author ....ee........eeeeee....eeeeeee....eeeehhhhhhh...eeeee............eee.eeeeee.............eeeee................hhhhhhhhh....eeeeee..............eeeeeeeehhhhhhhhh.......eeee................eeeeee..eeeeeeeeee..........eeeee...hhhhhhhhh... Sec.struct. author
                 SAPs(SNPs) ---------------------------D--------------------------R--------------K-----------------N----W----------M-----------K-------M----S--C-------P-------AS------F-------------R-S-------------RD--------------------------N--------------------- SAPs(SNPs)
                PROSITE (1) TRYPSIN_DOM  PDB: A:16-243 UniProt: 235-467                                                                                                                                                                                              -- PROSITE (1)
                PROSITE (2) -------------------------------------TRYPSI---------------------------------------------------------------------------------------------------------------------------------------TRYPSIN_SER --------------------------------------------- PROSITE (2)
           Transcript 1 (1) ---------------Exon 1.8e  PDB: A:31-69 UniProt: 250-289------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Transcript 1 (1)
           Transcript 1 (2) Exon 1.7a      ---------------------------------------Exon 1.9c  PDB: A:69-245 (gaps) UniProt: 289-488 [INCOMPLETE]                                                                                                                         Transcript 1 (2)
                2vwn A   16 IVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGEQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTR  245
                                    25        35        45        55      | 64        74        84        94       104       114       124|     131B       141   ||  152       162       172       182   ||  190       200       210       221  |    230       240     
                                                                        61A                                                            124A    131A|           145|                                   185A|                              218|   |                      
                                                                                                                                                131B            147                                    185B                               220   |                      
                                                                                                                                                                                                                                             223A

Chain L from PDB  Type:PROTEIN  Length:45
 aligned with FA10_HUMAN | P00742 from UniProtKB/Swiss-Prot  Length:488

    Alignment length:52
                                   137       147       157       167       177  
          FA10_HUMAN    128 LCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLER  179
               SCOP domains d2vwnl_ L: auto    mated matche   s                  SCOP domains
               CATH domains 2vwnL00 L:88-13    9 Laminin                         CATH domains
               Pfam domains ---------------------------------------------------- Pfam domains
         Sec.struct. author ...hhhhhh..eee.----.eee....eee.---..eee............. Sec.struct. author
                 SAPs(SNPs) --------------K------Y-YT--------------------------- SAPs(SNPs)
                PROSITE (1) ---------------------EGF_2           --------------- PROSITE (1)
                PROSITE (2) ---------------------------------------------------- PROSITE (2)
           Transcript 1 (1) Exon 1.6c  PDB: L:88-128 (gaps)          ----------- Transcript 1 (1)
           Transcript 1 (2) ----------------------------------------Exon 1.7a    Transcript 1 (2)
                2vwn L   88 LCSLDNGDCDQFCHE----VVCSCARGYTLA---KACIPTGPYPCGKQTLER  139
                                    97    |  107       117|   |  127       137  
                                        102  107        118 122

Legend:		→ Mismatch	(orange background)
	-	→ Gap	(green background, '-', border residues have a numbering label)
		→ Modified Residue	(blue background, lower-case, 'x' indicates undefined single-letter code, labelled with number + name)
	x	→ Chemical Group	(purple background, 'x', labelled with number + name, e.g. ACE or NH2)
	extra numbering lines below/above indicate numbering irregularities and modified residue names etc., number ends below/above '\|'

Classification and Annotation

SCOP Domains (2, 2)

CATH Domains (2, 3)

Pfam Domains (1, 1)

Gene Ontology (22, 22)

Asymmetric Unit(hide GO term definitions)

Chain A,L (FA10_HUMAN | P00742)

molecular function
	GO:0005509	calcium ion binding	Interacting selectively and non-covalently with calcium ions (Ca2+).
	GO:0016787	hydrolase activity	Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.
	GO:0008233	peptidase activity	Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.
	GO:0005543	phospholipid binding	Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
	GO:0004252	serine-type endopeptidase activity	Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).
	GO:0008236	serine-type peptidase activity	Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).
biological process
	GO:0006888	ER to Golgi vesicle-mediated transport	The directed movement of substances from the endoplasmic reticulum (ER) to the Golgi, mediated by COP II vesicles. Small COP II coated vesicles form from the ER and then fuse directly with the cis-Golgi. Larger structures are transported along microtubules to the cis-Golgi.
	GO:0007596	blood coagulation	The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.
	GO:0007598	blood coagulation, extrinsic pathway	A protein activation cascade that contributes to blood coagulation and consists of the self-limited process linking exposure and activation of tissue factor to the activation of clotting factor X.
	GO:0007597	blood coagulation, intrinsic pathway	A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.
	GO:0007599	hemostasis	The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.
	GO:0017187	peptidyl-glutamic acid carboxylation	The gamma-carboxylation of peptidyl-glutamic acid; catalyzed by the vitamin K dependent gamma-glutamyl carboxylase.
	GO:0030335	positive regulation of cell migration	Any process that activates or increases the frequency, rate or extent of cell migration.
	GO:0051897	positive regulation of protein kinase B signaling	Any process that activates or increases the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
	GO:0006508	proteolysis	The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.
	GO:0006465	signal peptide processing	The proteolytic removal of a signal peptide from a protein during or after transport to a specific location in the cell.
cellular component
	GO:0005796	Golgi lumen	The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks.
	GO:0005788	endoplasmic reticulum lumen	The volume enclosed by the membranes of the endoplasmic reticulum.
	GO:0005576	extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
	GO:0031233	intrinsic component of external side of plasma membrane	The component of a plasma membrane consisting of gene products and protein complexes that penetrate the external side of the plasma membrane only, either directly or via some covalently attached hydrophobic anchor.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Visualization

Interactive Views

Asymmetric Unit
	Complete Structure
		Jena3D(integrated viewing of ligand, site, SAP, PROSITE, SCOP information)
		WebMol \| AstexViewer[tm]@PDBe (Java Applets, require no local installation except for Java; loading may be slow)
		STRAP (Java WebStart application, automatic local installation, requires Java; full application with system access!)
		RasMol (require local installation)
		Molscript (VRML) (requires installation of a VRML viewer; select preferred view via VRML and generate a mono or stereo PDF format file)

	Ligands, Modified Residues, Ions
		CA	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]
		CL	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]
		H25	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]
		NA	[ RasMol \| Jena3D ]	+environment [ RasMol \| Jena3D ]

	Sites
		AC1	[ RasMol ]	+environment [ RasMol ]
		AC2	[ RasMol ]	+environment [ RasMol ]
		AC3	[ RasMol ]	+environment [ RasMol ]
		AC4	[ RasMol ]	+environment [ RasMol ]
		AC5	[ RasMol ]	+environment [ RasMol ]
		AC6	[ RasMol ]	+environment [ RasMol ]

	Cis Peptide Bonds
(no "Cis Peptide Bonds" information available for 2vwn)

Biological Units
	Complete Structure
		Biological Unit 1	[ Jena3D ]
		Biological Unit 2	[ Jena3D ]
		Biological Unit 3	[ Jena3D ]

Still Images

Databases and Analysis Tools

Databases

Access by PDB/NDB ID
	2vwn
		Family and Domain Information	:	ProDom \| SYSTERS
		General Structural Information	:	GlycoscienceDB \| MMDB \| NDB \| OCA \| PDB \| PDBe \| PDBj \| PDBsum \| PDBWiki \| PQS \| PROTEOPEDIA
		Orientation in Membranes	:	OPM
		Protein Surface	:	SURFACE
		Secondary Structure	:	DSSP (structure derived) \| HSSP (homology derived)
		Structural Genomics	:	GeneCensus
		Structural Neighbours	:	CE \| VAST
		Structure Classification	:	CATH \| Dali \| SCOP
		Validation and Original Data	:	BMRB Data View \| BMRB Restraints Grid \| EDS \| PROCHECK \| RECOORD \| WHAT_CHECK

Access by UniProt ID/Accession number
	FA10_HUMAN \| P00742
		Comparative Protein Structure Models	:	ModBase
		Genomic Information	:	Ensembl
		Protein-protein Interaction	:	DIP
		Sequence, Family and Domain Information	:	InterPro \| Pfam \| SMART \| UniProtKB/SwissProt

Access by Enzyme Classificator (EC Number)
	3.4.21.6
		General Enzyme Information	:	BRENDA \| EC-PDB \| Enzyme \| IntEnz
		Pathway	:	KEGG \| MetaCyc

Access by Disease Identifier (MIM ID)
	227600
		Disease Information	:	OMIM

Access by GenAge ID
	(no 'GenAge ID' available)
		Age Related Information	:	GenAge

Analysis Tools

Related Entries

Entries Sharing at Least One Protein Chain (UniProt ID)

Related Entries Specified in the PDB File

1c5m	STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1ezq	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515
1f0r	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815
1f0s	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208707
1fax	COAGULATION FACTOR XA INHIBITOR COMPLEX
1fjs	CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031)COMPLEXED WITH FACTOR XA
1g2l	FACTOR XA INHIBITOR COMPLEX
1g2m	FACTOR XA INHIBITOR COMPLEX
1hcg	BLOOD COAGULATION FACTOR XA
1ioe	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55532
1iqe	HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55590
1iqf	HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55165
1iqg	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55159
1iqh	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55143
1iqi	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55125
1iqj	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55124
1iqk	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M55113
1iql	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54476
1iqm	HUNMAN COAGULATION FACTOR XA COMPLEXD WITH M54471
1iqn	HUMAN COAGULATION FACTOR XA COMPLEXD WITH M55192
1ksn	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH FXV673
1kye	FACTOR XA IN COMPLEX WITH (R)-2-(3- ADAMANTAN-1-YL-UREIDO)-3-(3-CARBAMIMIDOYL- PHENYL)-N-PHENETHYL-PROPIONAMIDE
1lpg	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
1lpk	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
1lpz	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1lqd	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1mq5	CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(4-CHLOROPHENYL)AMINO]CARBONYL]PHENYL]- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITHHUMAN FACTOR XA
1mq6	CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO -2-[[(5-CHLORO-2-PYRIDINYL)AMINO]CARBONYL ]-6-METHOXYPHENYL]-4-[[(4,5-DIHYDRO-2- OXAZOLYL)METHYLAMINO]METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1msx	HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N- AMINO-15N-IMINO-13C-METHYL)PHENOXY]-6-[3 -(15N-AMINO-13C-METHYL)PHENOXY]-3,5- DIFLUORO-4-METHYLPYRIDINE (ZK-806299), BINDING MODELFROM DOUBLE REDOR NMR AND MD SIMULATIONS.
1nfu	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH RPR132747
1nfw	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH RPR209685
1nfx	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH RPR208944
1nfy	CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXEDWITH RPR200095
1nl8	THEORETICAL MODEL OF THE TISSUE FACTOR/ FACTOR VIIA/FACTORXA COMPLEX
1p0s	CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEXWITH ECOTIN M84R
1v3x	FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5, 4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4 -(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE
1wu1	FACTOR XA IN COMPLEX WITH THE INHIBITOR 4 -[(5-CHLOROINDOL-2-YL)SULFONYL]-2-(2- METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL)PYRIMIDIN -2-YL]CARBONYL]PIPERAZINE
1xka	FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'-AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1xkb	FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S) -(3'-AMIDINO-3- BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1z6e	CRYSTAL STRUCTURE OF FACTOR XA COMPLEXED TO RAZAXABAN
2bmg	CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50
2boh	CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 1
2bok	FACTOR XA - CATION
2bq6	CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21
2bq7	CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43
2bqw	CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
2cji	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2fzz	FACTOR XA IN COMPLEX WITH THE INHIBITOR 1 -(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2 '-(((3R)-3-HYDROXY-1-PYRROLIDINYL)METHYL)-4 -BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6- TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7- ONE
2g00	FACTOR XA IN COMPLEX WITH THE INHIBITOR 3 -(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL )-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7- TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1- YL)BENZAMIDE
2gd4	CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX
2j2u	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2j34	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2j38	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2j4i	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2j94	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2j95	CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2jkh	FACTOR XA - CATION INHIBITOR COMPLEX
2uwl	SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2uwo	SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2uwp	FACTOR XA INHIBITOR COMPLEX
2vh0	STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS:BIARYL PYRROLIDIN-2- ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS
2vh6	STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS
2vvc	AMINOPYRROLIDINE FACTOR XA INHIBITOR
2vvu	AMINOPYRROLIDINE FACTOR XA INHIBITOR
2vvv	AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
2vwl	AMINOPYRROLIDINE FACTOR XA INHIBITOR
2vwm	AMINOPYRROLIDINE FACTOR XA INHIBITOR
2vwo	AMINOPYRROLIDINE FACTOR XA INHIBITOR
2w26	FATOR XA IN COMPLEX WITH BAY59-7939
2w3i	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4 ,4-DISUBSTITUTED PYRROLIDINE-1,2- DICARBOXAMIDE INHIBITOR 2
2w3k	CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4 ,4-DISUBSTITUTED PYRROLIDINE-1,2- DICARBOXAMIDE INHIBITOR 1

Description

Compounds

Structural Features

Chains, Units

Ligands, Modified Residues, Ions (4, 6)